Leishmania vaccine

Details Leishmania vaccine Leishmania vaccine

2005-05-10

2005-05-10

Smith, Lynette R.F. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Parasitic organism or component thereof or substance...

C424S184100, C424S093200, C424S093210, C435S069100, C435S071100, C435S442000, C435S375000, C435S245000, C435S243000, C435S258300, C435S947000, C514S679000

Reexamination Certificate

active

06890542

ABSTRACT:
The present invention relates to the use of a live mutantLeishmaniain the preparation of a vaccine and to vaccine formulations for use in immunizing mammals, such as dogs and/or humans. The mutantLeishmaniacomprises at least one defective cysteine proteinase gene.

REFERENCES:
patent: 5726292 (1998-03-01), Lowell
patent: 5827671 (1998-10-01), Matlashewski et al.
patent: 5863775 (1999-01-01), Atkinson et al.
patent: 5955333 (1999-09-01), Beverley et al.
patent: 5965143 (1999-10-01), Fasel et al.
patent: 6020144 (2000-02-01), Gueiros-Filho et al.
patent: 6133017 (2000-10-01), Matlashewski et al.
patent: 6162638 (2000-12-01), Papadopoulou et al.
patent: 6331304 (2001-12-01), Papadopoulou et al.
patent: 6403081 (2002-06-01), Papadopoulou et al.
patent: 6426203 (2002-07-01), Papadopoulou et al.
patent: 9506729 (1995-03-01), None
patent: 9844943 (1998-10-01), None
patent: 9951264 (1999-10-01), None
Omara-Opyene, Al et al, Molecular and Biochemical Parasitology, vol. 90, pp. 247-267, Dec. 1997.*
Cottnez-Detoefu, M. et al. “Vitro and In Vivo Effects of Interleukin 2 or Protozoan Parasite Leishmania.”Eur. J. Immunol.19:(3):487-491 (Mar. 1989).
Cox, F.E. “Designer Vaccines for Parasitic Diseases.”International Journal for Parasitology.27(10):1147-1157 (Oct. 1997) Abstract Only.
Denise, H. et al. “Expression of MultipleCPBGenes Encoding Cysteine Proteases Is Required forLeishmania mexicanaVirulence In Vivo.”Infection and Immunity3190-3195 (Jun. 2003).
Lagardere B. “Future Vaccines in Parasitology.”Bulletin de la Societe de Pathologiec Exotique84(5 pt 5):926-934(1990) Abstract Only.
Bart, G et al. “Cathepsin B-like Cysteine Proteinase-Deficient Mutants of Leishmania Mexicana”Molecular and biochemical parasitology.88(1-2):53-61 (Sep. 1997).
Bart, G et al. “Isolation of Imepe, a gene encoding a Leishmania mexicana cathepsin-B-like cysteine proteinase.”Molecular and Biochemical Parasitology.73(1-2):271-274 (Jul. 1995).
Boslego et a.Vaccines and Immunotherapy.Chapter 17: 211-223, (1991).
Ellis, RW.Vaccines, New Technologies for making vaccinesChapter 29:569-574, WB Saunders Company (1998).
Gueiros-Filho et al.;Selection against the Dihydrofolate Reductase-Thymidylate Synthase(DHFR-TS)Locus as a Probe of Genetic Alternations in Leishmania major, Molecular and Cellular Biology,16:5655-5663 (Oct. 1996).
Mottram, JC et al. “A developmentally regulated cysteine proteinase gene of Leishmania mexicana”Molecular microbiology6(14):1925-1932 (Jul. 1992).
Mottram, JC., et al. “The multiple cpb Cysteine Proteinase Genes of Leishmania Mexicana Encode Isoenzymes that Differ in their Stage Regulation and Substrate Preferen”Journal of Biological Chemistry.272(22):14285-14293 (May 30, 1997).
Mottram, JC., et al. “Evidence from disruption of the Imcpb Gene Array of Leishmania Mexicana that Cysteine Proteina” Proceedingsof the National Academy of Sciences of the United States of America.93(12):6008-6013 (Jun. 11, 1996) (Abstract only).
Omara-Opyene, Al et al.Molecular and Biochemical Parasitology.90:247-267 (1997).
Robertson et al.;Parasite cysteine proteinases; Perspectives in Drug Discovery and Design,6:99-118 (Jun. 1996).
Souza, Ae et al. “Null Mutants for the Imcpa Cysteine Proteinase Gene in Leishmania Mexicana”Molecular and Biochemical Parasitology.63(2):213-220 (Feb. 1994).
Souza, AE et al. “Characterization of a multi-copy gene of a major stage specific cysteine proteinase of Leishmania mexicana”FEBS Letters311(2):124-127. (Oct. 19, 1992).
Titus et al.;Development of a safe live Leishmania vaccine line by gene replacement, Proc. Natl Acad Sci USA92:10267-10271 (Oct. 1995).
Tobin et al.;Transfected Leishmania Expressing Biologically Active IFN-y1,The Journal of Immunology,150, No. 11:5059-5069 (Jun. 1993).
Wolfram, M et al. “Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires”European Journal of Immunology.25(4):1094-1100. (Apr. 1995).

Affiliated with

Also associated with

Rating

Leishmania vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Leishmania vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leishmania vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3409639